This work was supported by the Council of Scientific and Industrial Research (CSIR) (project title: Comparative Genomics and Biology of Noncoding RNA), India. We also thank Dr. Teena Goel for helping with the in silico docking studies.
The Tuberculosis Drug Streptomycin as a Potential Cancer Therapeutic: Inhibition of miR-21 Function by Directly Targeting Its Precursor†
Article first published online: 15 DEC 2011
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 51, Issue 4, pages 1019–1023, January 23, 2012
How to Cite
Bose, D., Jayaraj, G., Suryawanshi, H., Agarwala, P., Pore, S. K., Banerjee, R. and Maiti, S. (2012), The Tuberculosis Drug Streptomycin as a Potential Cancer Therapeutic: Inhibition of miR-21 Function by Directly Targeting Its Precursor. Angew. Chem. Int. Ed., 51: 1019–1023. doi: 10.1002/anie.201106455
- Issue published online: 17 JAN 2012
- Article first published online: 15 DEC 2011
- Manuscript Received: 12 SEP 2011
- Council of Scientific and Industrial Research (CSIR)
- drug discovery;
- gene expression;
No dice: MicroRNAs (miRNAs) fine-tune gene expression, deregulation of which has been causally associated with a number of debilitating conditions. Streptomycin, a well-known aminoglycoside drug, binds to RNA secondary structures and is shown to inhibit miR-21 function by direct binding to its precursor, thus presumably interfering with the processing by the Dicer enzyme (see scheme).